Greenleaf Trust Has $13.86 Million Stock Holdings in AbbVie Inc. $ABBV

Greenleaf Trust decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 60,669 shares of the company’s stock after selling 4,032 shares during the quarter. Greenleaf Trust’s holdings in AbbVie were worth $13,862,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the 3rd quarter valued at $31,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at $26,000. Finally, Caitlin John LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABBV. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Down 0.2%

Shares of NYSE:ABBV opened at $206.21 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company’s 50-day moving average price is $220.95 and its two-hundred day moving average price is $224.28. The firm has a market cap of $364.61 billion, a P/E ratio of 87.38, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 EPS. The company’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New dermatology data for Skyrizi (risankizumab) and Rinvoq (upadacitinib) presented at the AAD strengthen AbbVie’s immunology/dematology growth story — includes long‑term safety, QoL outcomes and FDA label updates for Skyrizi (scalp/genital psoriasis) plus early Phase 3 vitiligo/alopecia signals that could expand indications and market share. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst optimism: JPMorgan calls the recent pullback a buying opportunity and maintains a $260 price target, signaling conviction that longer-term growth (Skyrizi/Rinvoq) and valuation upside remain intact. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target
• Positive Sentiment: Some investors view the company’s recent guidance cut and one‑time R&D charge as noise; bullish commentary reiterates buy ratings based on durable cash flow, strong pipeline, and dividend profile. AbbVie: Lowered Guidance Is Just Noise – Reiterate Buy
• Positive Sentiment: Dividend track record continues to support income investors — articles highlighting AbbVie as a reliable high-yield name add to investor confidence. This Pharma Dividend Has Been Raised Every Single Year for Over a Decade
• Neutral Sentiment: Ongoing observational Parkinson’s study in Belgium is being tracked for real‑world effectiveness signals; data could inform future label/market opportunities but isn’t an immediate revenue driver. AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch
• Negative Sentiment: Pricing risk: AbbVie listed Humira on the TrumpRx platform with a steep (~86%) discount — a politically driven pricing move that could pressure Humira revenue and raises questions about U.S. pricing strategy for legacy brands. This is a material headline given Humira’s past revenue contribution. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Guidance and one‑time charges: AbbVie lowered Q1 and FY‑2026 outlook after taking a $744M R&D charge; that prompted near‑term earnings uncertainty and contributed to the recent share pullback. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.